Log in to save to my catalogue

Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With An...

Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With An...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9270693

Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Publication information

Publisher

Chicago: American Medical Association

More information

Scope and Contents

Contents

Importance Older patients are underrepresented in studies of rituximab for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. Little is known about outcomes and adverse events associated with the use of rituximab therapy among patients 75 years and older with ANCA-associated vasculitis. Objective To examine outcomes...

Alternative Titles

Full title

Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9270693

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9270693

Other Identifiers

ISSN

2574-3805

E-ISSN

2574-3805

DOI

10.1001/jamanetworkopen.2022.20925

How to access this item